Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates

Time: 5:00 pm
day: Day One


  •  Review CD37 as target for radioimmunotherapy
  • Analyse preclinical and clinical data for treatment of non-Hodgkin lymphoma with the beta-emitting radioimmunoconjugate 177Lulilotomab satetraxetan (Betalutin®)
  • Evaluate preclinical data for treatment of chronic lymphocytic leukaemia and non-Hodgkin lymphoma with the alpha emitting radioimmunoconjugate 212Pb-TCMCNNV003 (Alpha37)